Sidley represented BigHat Biosciences (BigHat), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, in a strategic collaboration with Eli Lilly and Company (Lilly). In this collaboration, BigHat will deploy its Milliner platform, a suite of state-of-the-art ML technologies integrated with a synthetic biology-based high-speed wet lab, to design and engineer therapeutic antibodies with superior functionality.
BigHat and Lilly will collaborate to design and discover next-generation antibodies for up to two antibody therapeutic programs. This partnership aims to design, engineer, and develop antibodies with enhanced functionality and improved biophysical properties to create therapeutics that will benefit patients with chronic disease.
This collaboration builds on BigHat’s strategy to engage in value-generating strategic partnerships balanced with an exciting internal pipeline of proprietary therapeutics in the areas of oncology and immunology. BigHat’s ML-powered platform is designed to tackle molecular engineering challenges and unlock the development of novel therapeutics for the improvement of patient outcomes.
The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions) and Alison Lehner (Emerging Companies and Venture Capital), and it included Longbo Wang (Technology and Life Sciences Transactions).
For additional information, please refer to the press release.
